SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort studyArticle Published on 2022-12-012022-10-06 Journal: Lancet Reg Health Am [Category] 진단, [키워드] age All participant anti-SARS-CoV-2 BNT162b2 BNT162b2 vaccine booster Care cohort study CoronaVac COVID-19 determine dose effective end point General population groups Heterologous heterologous vaccine homologous humoral immune response IFN-γ IgG antibody IL-2 inactivated kidney liver median Medicine more difficult mRNA mRNA vaccine neutralising antibody not differ of BNT162b2 outcome Patient priming proportion Prospective prospective cohort study recipient recipients Red SARS-CoV-2 SARS-CoV-2 vaccine School secondary secreting significantly significantly higher solid organ solid organ transplant SOT T-cell T-cell responses vaccination Vaccine vaccine immunogenicity. women [DOI] 10.1016/j.lana.2022.100371 PMC 바로가기 [Article Type] Article
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trialArticle Published on 2022-12-012022-10-06 Journal: The Lancet Regional Health - Western Pacific [Category] 진단, [키워드] acute respiratory syndrome Administered Adults adverse event AEs age analysis assessment assigned BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine China Chinese clinical trial Complete Completed conducted coronavirus COVID-19 development dose double-blind Efficacy and safety enrolled Follow-up geometric mean titer GMT GMTs Han Chinese healthy immune response immunogenicity immunogenicity endpoint Inc independent individual injection intramuscular Intramuscular injection investigators Laboratory parameters management messenger Messenger RNA Mild moderate mRNA vaccine Neutralising Antibodies neutralising antibody of BNT162b2 participant Participants pharmaceutical Placebo placebo-controlled trial randomisation randomised Randomly reactogenicity receive recipients recruited reduced remained reported resolved Result robust Safety SARS-CoV-2 SARS-CoV-2 variant SCR second dose sera serious AE seroconversion rate severity Shanghai Sponsor statisticians stratified T-cell Response the placebo group Tolerability Treatment Trial utilised vaccination vaccination. vaccine administration were blinded [DOI] 10.1016/j.lanwpc.2022.100586 PMC 바로가기 [Article Type] Article
The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: a prospective observational cohort study단일 의료 시스템에서 의료 종사자들 사이에서 BNT162b2 백신 접종 후 SARS-CoV-2 스파이크 단백질에 대한 부작용과 면역 반응 사이의 연관성: 전향적 관찰 코호트 연구Observational Study Published on 2022-11-302022-09-12 Journal: Human vaccines & immunotherapeutics [Category] MERS, SARS, 임상, 진단, [키워드] administration Adverse Adverse reaction Anti-spike IgG antibody anti-spike IgG level Antibody titer association Asthma BNT162b2 BNT162b2 vaccine conducted COVID-19 Cutoff determine Factor first dose healthcare healthcare worker help humoral humoral immune response Humoral response IgG IgG level immune response information Local majority median median age mRNA mRNA vaccine of BNT162b2 participant Participants prospective observational cohort reaction recipients recruited reported SARS-CoV-2 anti-spike IgG SARS-CoV-2 spike protein second dose significantly higher systemic adverse reactions Systemic adverse reactions. systemic reaction vaccination Vaccine was collected were measured with COVID-19 women [DOI] 10.1080/21645515.2022.2048559 PMC 바로가기 [Article Type] Observational Study
An additional dose of viral vector COVID-19 vaccine and mRNA COVID-19 vaccine in kidney transplant recipients: A randomized controlled trial (CVIM 4 study)Article Published on 2022-11-012022-11-15 Journal: American journal of transplantation : official jou [Category] COVID19(2023년), SARS, 진단, [키워드] age anti-RBD antibody B cell response BNT162b2 booster Cell-mediated immunity ChAdOx1 ChAdOx1 nCoV-19 comparable Coronavirus disease 2019 COVID-19 COVID-19 vaccine dose elicit group humoral immunization Immunocompromised immunogenicity investigated IQR kidney transplant male median mononuclear cells mRNA mRNA-1273 mRNA-1273. no difference participant Peripheral blood positive Randomized Randomized controlled trial receive recipients response SARS-CoV-2 seroconversion rate significantly statistically T cell Vaccine Viral vector virus neutralization test [DOI] 10.1111/ajt.17151 PMC 바로가기
Incidence and outcome of SARS-CoV-2 infection in a pediatric kidney transplant recipient cohort from a single center in Northern ItalyArticle Published on 2022-11-012022-11-16 Journal: Pediatric transplantation [Category] COVID19(2023년), SARS, 치료기술, [키워드] adolescents children clinically Cohort concern contrary COVID-19 criteria detect duration of symptom Effect eight enrolled epidemiological high risk hospital Immunocompromised patients incidence IQR Italy kidney kidney transplant mortality rate Nasopharyngeal swab observation period outcome Patient pediatric pediatric kidney transplant pediatric transplantation performed Population positive patients positive RT-PCR recipient recipients renal required risk RT-PCR RT-PCR test RT-PCR testing SARS-CoV-2 SARS-COV-2 infection severe COVID-19 single center solid organ transplant solid organ transplant. solid organ transplantation SOT specific treatment Swab symptomatic Test tested the healthy therapy [DOI] 10.1111/petr.14335 PMC 바로가기
Association between SARS-CoV-2 infection and de novo HLA donor specific antibody production in lung transplant recipients: Single-center studyArticle Published on 2022-11-012022-11-15 Journal: Human immunology [Category] SARS, 진단, 치료기술, [키워드] antibody antibody production association COVID-19 COVID-19 pandemic de novo diagnosed with COVID-19 Diagnosis Donor donor specific antibodies HLA HLA antibodies HLA class I incidence include Infection LTR lung transplant lung transplant. MFI morbidity and mortality no significant difference outcome performed raised recipient recipients respiratory retrospective SARS-COV-2 infection the median viral infection [DOI] 10.1016/j.humimm.2022.07.007 PMC 바로가기
Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine RecipientsArticle Published on 2022-10-292022-11-15 Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] ACE2 acute respiratory syndrome antibodies antibodies. antibody binding coronavirus coronavirus 2 COVID-19 individual inhibited levels of antibody messenger Messenger RNA no difference omicron recipient recipients respiratory response responses against RNA SARS-CoV-2 significantly lower Spike protein T cells T-cell Response T-cell responses Vaccine vaccine strain variant while [DOI] 10.1093/cid/ciac305 PMC 바로가기
Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sourcesArticle Published on 2022-10-292022-11-15 Journal: Nature Communications [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] anti-SARS-CoV-2 Antibody titer CCP collected convalescent plasma COVID-19 Donor dose effective geometric geometric mean titer Immune escape Immunocompromised implication Infection lesson monoclonal antibodies monoclonal antibody mRNA vaccine neutralization neutralize Neutralizing Neutralizing antibody titer omicron Outpatient pandemic plasma plasma activity provide recipients reduction representing SARS-CoV-2 variant sera subject therapeutic Therapies uninfected vaccinee variant variants of concern [DOI] 10.1038/s41467-022-33864-y PMC 바로가기
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort studyArticle Published on 2022-10-272022-11-15 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI Ad26.COV2.S Ad26.COV2.S vaccine age Analysis anti-SARS-CoV-2 Anti-spike antibody Antibody Response Antiretroviral therapy approved assays BNT162b2 CD4+ T-cell CD8+ T-cell ChAdOx1-S comparable Concentration conducted Control controls COVID-19 defined ELISPOT Endpoint Environment Final generally mild geometric HIV HIV-negative IFN-γ immunogenic immunogenicity Increased IQR less maintain male marker median age mRNA vaccination mRNA vaccine mRNA-1273 mRNA-based vaccines Netherland Netherlands of BNT162b2 PLWH predicted primary endpoint prospective cohort study Public reactogenicity receiving recipients reduced Registered remained required response SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 spike peptide SARS-CoV-2 vaccination SARS-CoV-2 vaccine secondary Serious Adverse Events serological response Sex suppressed T-cell Response the median the vaccine Trial vaccination Vaccine vaccine group Viral load with HIV [DOI] 10.1371/journal.pmed.1003979 PMC 바로가기
SARS-CoV-2 anti-spike antibodies after a fourth dose of COVID-19 vaccine in adult solid-organ transplant recipientsArticle Published on 2022-10-192022-11-15 Journal: Vaccine [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] age anti-spike antibody antibodies Antibody titer booster conducted COVID-19 COVID-19 vaccine detectable dose doses fourth dose had more humoral immune response IQR kidney transplant recipients liver transplant no statistical difference Organ transplant participant patients proportion receiving recipient recipients regimen retrospective SARS-CoV-2 SARS-CoV-2 vaccine significantly higher solid-organ transplant Solid-organ transplantation SOT tested third dose vaccination. Vaccine vaccine doses vaccine injection [DOI] 10.1016/j.vaccine.2022.08.065 PMC 바로가기